Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$240.74 USD

240.74
203,030

+0.75 (0.31%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $240.81 +0.07 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain HOLX Stock in Your Portfolio Now

by Zacks Equity Research

Hologic's strength in the Surgical wing instills optimism among investors. Yet, currency impacts raise concerns.

Zacks Equity Research

Here's Why You Should Hold IART Stock in Your Portfolio Now

by Zacks Equity Research

Integra's growth within its Tissue Technologies business segment bolsters investors' confidence in the stock.

Zacks Equity Research

New Product Offerings Support QIAGEN's Shares Amid Currency Woes

by Zacks Equity Research

To support internal growth, QIAGEN is investing heavily in R&D for menu expansion of its key platforms.

Zacks Equity Research

STERIS Gains From Expanded Product Offerings Amid Macro Issues

by Zacks Equity Research

STE expects bioprocessing revenues to grow in the second half of fiscal 2025.

Zacks Equity Research

Reasons to Retain AMED Stock in Your Portfolio Now

by Zacks Equity Research

Amedisys' expected merger with UnitedHealth Group's Optum brings optimism to investors. Yet, a dull macroeconomic condition adds to the worry.

Zacks Equity Research

Growing Biosimilars Business, New Partnerships Support ABT Stock

by Zacks Equity Research

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Zacks Equity Research

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

by Zacks Equity Research

Veracyte's progress with key drivers and the strength in its diagnostics tests bring optimism to investors.

Zacks Equity Research

ZBH Stock to Benefit From Global Expansion Despite Macro Issues

by Zacks Equity Research

Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.

Zacks Equity Research

Labcorp's New Alliance With Graves Gilbert Clinic Set to Boost Stock

by Zacks Equity Research

LH announces strategic agreement with Graves Gilbert Clinic for lab operations.

Zacks Equity Research

Lucid Inks New Partnership With VITALExam: Stock to Gain?

by Zacks Equity Research

LUCD collaborates with VITALExam to enhance access to the EsoGuard Esophageal DNA Test. The partnership launches a fully contracted testing event for Tuscaloosa firefighters.

Zacks Equity Research

Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Penumbra (PEN) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Here's Why You Should Add HAE Stock to Your Portfolio Now

by Zacks Equity Research

Strong prospects for the Plasma franchise and favorable solvency bode well for Haemonetics.

Zacks Equity Research

Reasons to Add GMED Stock to Your Portfolio Right Now

by Zacks Equity Research

Globus Medical's synergistic merger with NuVasive and a strong liquidity position bring optimism to investors.

Zacks Equity Research

Hologic Teams Up With the CDC to Combat H5N1 Bird Flu: Stock to Gain?

by Zacks Equity Research

Via an agreement with the CDC, Hologic is set to develop ASRs for launching the H5N1 bird flu test.

Zacks Equity Research

Here's Why Penumbra (PEN) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Align Shares Down on Macroeconomic Issues, ASP Challenges

by Zacks Equity Research

ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This results in a decline in the company's revenues.

Zacks Equity Research

Bruker Adds Another 1.2 GHz NMR System in Switzerland, Stock Climbs

by Zacks Equity Research

Bruker announces a 1.2 GHz NMR spectrometer at the Swiss High-field NMR facility.

Zacks Equity Research

Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain?

by Zacks Equity Research

TECH enters a co-marketing and co-promotion agreement with Waters Corporation to expand the reach of advanced biotherapeutic characterization and development processes.

Sridatri Sarkar headshot

4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2025

by Sridatri Sarkar

Investing in large-cap MedTech stocks like MCK, PEN, CAH and PEN can be profitable for investors in 2025.

Zacks Equity Research

MYGN Stock Might Gain From the New Recognition of RiskScore Study

by Zacks Equity Research

The American Journal of Human Genetics names Myriad Genetics' RiskScore study as one of the top 10 significant advances in genomic medicine.

Zacks Equity Research

Reasons to Ratain CVS Stock in Your Portfolio Now

by Zacks Equity Research

Investors feel optimistic about CVS Health's 2025 roadmap. Yet, poor macroeconomic conditions are concerning.

Zacks Equity Research

Reasons to Retain ABT Stock in Your Portfolio Now

by Zacks Equity Research

Investors feel optimistic about Abbott's robust strength in the EPD and Nutrition businesses. Yet, unfavorable forex impacts are concerning.

Zacks Equity Research

Labcorp Launches H5 Bird Flu Test Amid US Outbreak: Stock to Gain?

by Zacks Equity Research

LH's new H5 bird flu test, developed in collaboration with the CDC, is now available in the United States.

Zacks Equity Research

Here's Why Penumbra (PEN) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker

by Zacks Equity Research

Abbott completes the world's first leadless pacing procedures in the left bundle branch of the heart.